Sign In
Buy DGX
$196.12
+2.45 (+1.27%)
At Close: Jun 04, 2026
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
03:57pm, Friday, 29'th Jul 2022 Zacks Investment Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
03:28pm, Friday, 29'th Jul 2022 Zacks Investment Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
Integer Holdings (ITGR) Q2 Earnings Miss, FY22 View Revised
02:13pm, Friday, 29'th Jul 2022 Zacks Investment Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales besides strength in the majority of product lines.
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
05:15pm, Thursday, 28'th Jul 2022 Zacks Investment Research
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down
05:14pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
04:50pm, Thursday, 28'th Jul 2022 Zacks Investment Research
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Thermo Fisher (TMO) Q2 Earnings Top Estimates, Margins Down
02:44pm, Thursday, 28'th Jul 2022 Zacks Investment Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Specialty Diagnostics segment revenues is disappointing.
West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut
01:53pm, Thursday, 28'th Jul 2022 Zacks Investment Research
West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.
Merit Medical (MMSI) Q2 Earnings Beat, FY22 View Revised
01:51pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth in both its segments and from all product categories within its Cardiovascular unit.
3 MedTech Stocks That are Likely to Beat This Earnings Season
12:23pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.
4 Analysts Have This to Say About Quest Diagnostics
06:38pm, Friday, 22'nd Jul 2022 Benzinga
Analysts have provided the following ratings for Quest Diagnostics (NYSE:DGX) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
3
0
0
Tenet Healthcare (THC) Q2 Earnings Beat, Trims '22 EPS View
03:51pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Tenet Healthcare's (THC) second-quarter earnings benefit from strong Ambulatory Care and Conifer segments. However, a trimmed EPS view for 2022 might raise concerns for investors.
Quest Diagnostics Incorporated (DGX) CEO Steve Rusckowski on Q2 2022 Results - Earnings Call Transcript
04:14pm, Thursday, 21'st Jul 2022
Quest Diagnostics Incorporated (NYSE:DGX ) Q2 2022 Earnings Conference Call July 21, 2022 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Steve Rusckowski - Chairman
Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View
02:03pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.
Quest Diagnostics (DGX) Tops Q2 Earnings and Revenue Estimates
12:05pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.42% and 4.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
